We are live on ! Find out more
ANTX icon

AN2 Therapeutics
ANTX

37 hedge funds and large institutions have $9.88M invested in AN2 Therapeutics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

13% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 8

6% more funds holding

Funds holding: 35 → 37 (+2)

1.33% more ownership

Funds ownership: 30.29% → 31.62% (+1.3%)

6% less capital invested

Capital invested by funds: $10.5M → $9.88M (-$633K)

Holders
37
Holders Change
+2
Holders Change %
+5.71%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
9
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$170K
2
Millennium Management
Millennium Management
New York
+$112K
3
Citadel Advisors
Citadel Advisors
Florida
+$108K
4
SCM
Stonepine Capital Management
Oregon
+$74.5K
5
AC
Almitas Capital
California
+$59.3K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$54.9K
2
Two Sigma Investments
Two Sigma Investments
New York
-$52.3K
3
LCM
Landscape Capital Management
New Jersey
-$28.9K
4
XT
XTX Topco
Cayman Islands
-$23.5K
5
AA
ACT Advisors
North Carolina
-$16.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Almitas Capital
California
$1.69M +$59.3K +50,806 +4%
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.23M – – –
P
3
Pfizer
New York
$815K – – –
SCM
4
Stonepine Capital Management
Oregon
$716K +$74.5K +63,755 +11%
PLC
5
Peapod Lane Capital
New York
$676K +$4.88K +4,180 +0.7%
Bank of Nova Scotia
6
Bank of Nova Scotia
Ontario, Canada
$523K – – –
LCM
7
Landscape Capital Management
New Jersey
$492K -$28.9K -24,703 -5%
Bank of Montreal
8
Bank of Montreal
Ontario, Canada
$481K – – –
Bank of America
9
Bank of America
North Carolina
$439K +$2 +2 +0%
Renaissance Technologies
10
Renaissance Technologies
New York
$386K -$54.9K -46,997 -12%
BlackRock
11
BlackRock
New York
$369K +$2.83K +2,424 +0.8%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$302K -$3.5K -3,000 -1%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$287K +$2.95K +2,524 +1%
Morgan Stanley
14
Morgan Stanley
New York
$262K +$45.6K +39,000 +20%
Two Sigma Investments
15
Two Sigma Investments
New York
$204K -$52.3K -44,819 -20%
WP
16
Woodline Partners
California
$166K +$170K +145,971 New
Citadel Advisors
17
Citadel Advisors
Florida
$132K +$108K +92,523 +402%
Millennium Management
18
Millennium Management
New York
$109K +$112K +95,683 New
State Street
19
State Street
Massachusetts
$99.2K – – –
RC
20
Rangeley Capital
Connecticut
$74.1K – – –
Squarepoint
21
Squarepoint
New York
$70.2K -$3.1K -2,655 -4%
BCM
22
Bridgeway Capital Management
Texas
$68.3K – – –
UBS Group
23
UBS Group
Switzerland
$64.6K -$30 -26 -0%
Northern Trust
24
Northern Trust
Illinois
$49.2K – – –
CAPTRUST Financial Advisors
25
CAPTRUST Financial Advisors
North Carolina
$45.6K – – –
1
2

ANTX Hedge Fund Activity: Q4 2025 in Review

37 of the 8,224 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q4 2025, worth a combined $9.88M — down 6% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ANTX positions and 3 closed out — a net gain of 2 holders — while 9 added to existing stakes and 8 trimmed.

The largest buyer was Woodline Partners, opening a new position worth an estimated $170K. The largest seller was Renaissance Technologies, cutting an estimated $54.9K.

  • 37 institutional investors held AN2 Therapeutics (ANTX) as of Q4 2025, up from 35 in Q3 2025.
  • Funds reported $9.88M of AN2 Therapeutics stock for Q4 2025, down 6% quarter-over-quarter.
  • 5 funds opened new AN2 Therapeutics positions in Q4 2025 and 3 closed out, a net change of +2 holders.
  • The largest AN2 Therapeutics buyer in Q4 2025 was Woodline Partners, an estimated $170K added.
  • The largest AN2 Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $54.9K sold.

Based on aggregated 13F filings for Q4 2025.